A Study of Additional Chemotherapy After Surgery for People With Malignant Peritoneal Mesothelioma
Trial Parameters
Brief Summary
The purpose of this study is to find out whether intraperitoneal or intravenous chemotherapy given after cytoreductive surgery and HIPEC are effective treatments for people with malignant peritoneal mesothelioma. Outcomes will be compared by observing intraperitoneal versus intravenous treatments to analyze if one is better than the other.
Eligibility Criteria
Inclusion Criteria: * Patient age 18 years or older, both sexes. * Clinical diagnosis of MPM at enrolling institution. * Prior to randomization, intraoperative pathologic confirmation of epithelioid MPM at enrolling institution. * Complete or near-complete CRS achieved. * Patient must be planning to undergo complete cytoreduction of all peritoneal disease. * ECOG performance status ≤ 1. * Hematology: ANC ≥ 1,500/µl. * Platelets \> 75,000/µl. * Adequate renal function: creatinine \< 1.5× the upper limit of normal (ULN) or calculated creatinine clearance of ≥50 ml/min. * Adequate hepatic function: bilirubin \< 1.5 mg/dl (except in patients with Gilbert's syndrome, who must have total bilirubin \< 3.0 mg/dL). * Women of childbearing potential with a negative pregnancy test result (urine or blood) who agree to use an effective contraceptive method. Reliable contraception should be used from trial screening and must be continued throughout the study. A woman of childbearing potential is def